SEC Form 4 · accession 0000899243-18-004829
Apellis Pharmaceuticals, Inc. · APLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven Axon
Officer — Chief Business Officer
Period of report
Feb 16, 2018
Accepted (ET)
Feb 21, 2018 · 5:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492422
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 20, 2018 | M | 38,610 | $2.59 | A | 38,610 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $14.95 | Feb 16, 2018 | A | 60,000 | A | — | Feb 15, 2028 | Common Stock | 60,000 | 60,000 | D |
| Stock Option (right to buy)F2 | $2.59 | Feb 20, 2018 | M | 38,610 | A | — | May 17, 2027 | Common Stock | 38,610 | 359,889 | D |
Explanation of responses
- F1This option was granted on February 16, 2018 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.
- F2This option was granted on May 18, 2017 and has vested as to 25% of the shares underlying the options on January 1, 2018, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through January 1, 2021, subject to continued service.